Increased risk of autoimmune thyroid disease in hepatitis C vs hepatitis B before, during, and after discontinuing interferon therapy

Archives of Internal Medicine

Volumn 158, Issue 13, 1998, Pages 1445-1448

  Fernandez Soto, Luisa ^a,b   Gonzalez, Amalia ^a   Escobar Jimenez, Fernando ^a   Vazquez, Rafael ^a   Ocete, Esther ^a   Olea, Nicolas ^a   Salmeron, Javier ^a  

^a Univ G   (Spain)

^b Edificio Saturno 4A ^*  (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; IMMUNOGLOBULIN; LIOTHYRONINE; THYROGLOBULIN ANTIBODY; THYROID ANTIBODY; THYROID PEROXIDASE; THYROID PEROXIDASE ANTIBODY; THYROTROPIN; THYROXINE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ANTIBODY TITER; ARTICLE; AUTOIMMUNE DISEASE; FEMALE; HASHIMOTO DISEASE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; SCREENING; SUBCUTANEOUS DRUG ADMINISTRATION; THYROID FUNCTION;

ADOLESCENT; ADULT; ANTIVIRAL AGENTS; AUTOANTIBODIES; FEMALE; HEPATITIS C; HUMANS; INTERFERON-ALPHA; IODIDE PEROXIDASE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECEPTORS, THYROTROPIN; RISK; THYROGLOBULIN; THYROID HORMONES; THYROIDITIS, AUTOIMMUNE;

EID: 0032527967     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.158.13.1445     Document Type: Article

References (24)

1. Tran A, Quaranta JF, Benzaken S, Thiers V, Chau HT, Hastier P. High prevalence of thyroid autoantibodies in a prospective series of patients with chronic hepatitis C before Interferon therapy. Hepatology. 1993;18:253-257.
2. Pawlotsky JM, Yahia MB, Andre CH, Voisin MC, Intrator L, Roudot-Thoraval F. Immunological disorders in C chronic active hepatitis: a prospective case-control study. Hepatology. 1994;19:841-848.
3. Tran A, Benzaken S, Braun HB, et al. Anti-Gor and anti-thyroid autoantibodies in patients with chronic hepatitis C. Clin Immunol Immunopathol. 1995;77:127-130.
4. Fernandez-Soto ML, Vazquez R, Olea N, et al. Disfuncion tiroidea y autoanticuerpos tiroideos en la hepatitis cronica C: efectos del Interferon [abstract]. Eur J Intern Med. 1994;2:123.
5. Marcellin P, Pouteau M, Benhamou JP. Hepatitis C virus infection, alpha interferon therapy and thyroid dysfunction. J Hepatol. 1995;22:364-369,
6. Roti E, Minelli R, Guiberti T, et al. Multiple changes in thyroid function in patients with chronic active HCV hepatitis treated with recombinant interferon-alpha. Am J Med. 1996;172;482-487.
7. Imagawa A, Itoh N, Hanafusa T, et al. Autoimmune endocrine disease induced by recombinant interferon-alpha therapy for chronic active type C hepatitis. J Clin Endocrinol Metab. 1995;80:922-926.
8. Tran A, Quaranta JF, Beusnel C, et al. Hepatitis C virus and Hashimoto's thyroiditis. Eur J Med. 1992;1:116-121.
9. Duclos-Vallee JC, Pateron D, Joannet C, Duron F, Homber JC, Beaugrand M. High prevalence of anti-HCV antibodies in patients with Hashimoto's thyroiditis [abstract]. J Hepatol. 1992;16:S56.
10. Saji M, Moriarty J, Ban T, Singer DS, Kohn LD. Major histocompatibility complex class I gene expression in rat thyroid cells is regulated by hormones, methimazole, and iodine as well as interferon. J Clin Endocrinol. 1992;75:871-878.
11. Chen LK, Mathieu-Mahul D, Bach FH, Dausset J, Bensussan A, Sasportes M. Recombinant interferon-alpha can induce rearrangement of T-cell antigen receptor alpha-chain and maturation to cytotoxicity in T-lymphocyte clones in vitro. Proc Natl Acad Sci U S A. 1986;83:4887-4889.
12. Fernandez-Soto ML, Campos MM, Gonzalez A, Barredo F, Olea N, Escobar-Jimenez F. Anticuerpos antitiroperoxidasa: estudio en sujetos sanos y con enfermedad tiroidea autoinmune. Endocrinologia. 1995;42:75-78.
13. Pateron D, Hartmann DJ, Duclos-Vallee JC, Jouanolle H, Beaugrand M. Latent autoimmune thyroid disease in patients with chronic HCV hepatitis. J Hepatol. 1992;16:244-245.
14. Preziati D, La Rosa L, Covini G, et al. Autoimmunity and thyroid function in patients with chronic active hepatitis treated with recombinant interferon alpha-2a. Eur J Endocrinol. 1995;132:587-593.
15. Lenzi M, Johnson PJ, McFarlane IG, et al. Antibodies to hepatitis C virus in autoimmune liver disease: evidence for geographical heterogeneity. Lancet. 1991; 338:277-280.
16. Prentice LM, Phillips DI, Sarsero D, Beever K, McLachlan SM, Smith BR. Geographical distribution of subclinical autoimmune thyroid disease in Britain: a study using highly sensitive direct assays for autoantibodies to thyroglobulin and thyroid peroxidase. Acta Endocrinol. 1990;123:493-498.
17. McFarlane IC, Path MR. Autoimmunity and hepatotropic viruses. Semin Liver Dis. 1991;11:223-233.
18. Deutsch M, Dourakis S, Manesis EK, et al. Thyroid abnormalities in chronic viral hepatitis and their relationship to interferon alfa therapy. Hepatology. 1997;26: 206-210.
19. Ronnblom LE, Alm GV, Obreg KE. Autoimmune phenomena in patients with malignant carcinoid tumors during interferon treatment. Acta Oncol. 1991;30: 537-540.
20. Marcellin P, Pouteau M, Renard P, et al. Sustained hypothyroidism induced by recombinant alpha interferon in patients with chronic hepatitis C. Gut. 1992;33: 855-856.
21. Baudin E, Marcellin P, Pouteau M, et al. Reversibility of thyroid dysfunction induced by recombinant alpha interferon in chronic hepatitis C. Clin Endocrinol. 1993;39:657-661.
22. Watanabe U, Hashimoto E, Hisamitsu T, Obata H, Hayashi N. The risk factor for development of thyroid disease during interferon-alpha therapy for chronic hepatitis C. Am J Gastroenterol. 1994;89:399-403.
23. Fernandez-Soto ML, Vazquez R, Gonzalez A, et al. Funcion y actividad inmune tiroidea en la hepatitis cronica: efecto del interferon [abstract]. Endocrinologia. 1994;41:22.
24. Yamazaki K, Kanaji Y, Shizume K, Yamakawa Y. Reversible inhibition by interferons alpha and beta of 1251 incorporation and thyroid hormone release by human thyroid follicles in vitro. J Clin Endocrinol Metab. 1993;77:1439-1441.